Medicine and Dentistry
Interstitial Lung Disease
100%
Idiopathic Pulmonary Fibrosis
74%
Diagnosis
52%
Patient
40%
Inpatient
37%
Chemotherapeutic Agent
35%
Combination Therapy
35%
Drug
34%
Fibrosis
29%
Sarcoidosis
25%
Body Mass Index
25%
Usual Interstitial Pneumonia
21%
Chest Imaging
21%
COVID-19
21%
Vaccine
21%
Crackle
21%
Hazard Ratio
20%
Diseases
19%
Hypersensitivity Pneumonitis
16%
Therapeutic Procedure
16%
Age
15%
Connective Tissue
12%
Lung
12%
Nintedanib
12%
Forced Vital Capacity
12%
Pulmonary Fibrosis
11%
Symptom
11%
Disease Exacerbation
9%
Clinical Management
8%
Development
8%
Deterioration
8%
Prevalence
8%
Male
7%
Lung Transplantation
7%
Chest
7%
Drug Therapy
7%
Motivation
7%
Clinician
7%
Patient Referral
7%
Treatment of Interstitial Lung Disease
7%
Early Diagnosis
7%
Computer Assisted Tomography
5%
Comprehension
5%
Granuloma
5%
Silo-Filler's Disease
5%
Epigenomics
5%
Transcriptomics
5%
Targeted Therapy
5%
Introspection
5%
Cytokine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosing Alveolitis
100%
Drug
71%
Interstitial Lung Disease
56%
Diseases
50%
Nintedanib
44%
Tolerability
43%
Pirfenidone
42%
Lung Fibrosis
31%
Fibrosis
25%
Sarcoidosis
25%
Azathioprine
21%
Vaccine
21%
Mycophenolate Mofetil
21%
Pneumonia
21%
Pamrevlumab
21%
Treprostinil
21%
Randomized Clinical Trial
17%
Allergic Pneumonitis
16%
Side Effect
14%
Antifibrotic Agent
12%
Pharmacotherapy
12%
Clinical Trial
12%
Lung Sarcoidosis
10%
Combination Therapy
8%
Pathogenesis
8%
Enalapril Maleate
8%
Pharmacodynamics
8%
Prevalence
8%
Symptom
7%
Adverse Event
7%
Pharmaceutical Therapy
7%
Preclinical Study
5%
Cytokine
5%
Granuloma
5%
Lung Disease
5%
Life Expectancy
5%